Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

S.E. Bowyer; A.D. Rao; M. Lyle; S. Sandhu; G. Long; G.A. Mcarthur; J.M. Raleigh; R.J. Hicks; Michael Millward

doi:10.1097/CMR.0000000000000099

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

S.E. Bowyer, A.D. Rao, M. Lyle, S. Sandhu, G. Long, G.A. Mcarthur, J.M. Raleigh, R.J. Hicks, Michael Millward

Research output: Contribution to journal › Article › peer-review

64 Citations (Web of Science)

Abstract

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.

Original language	English
Pages (from-to)	504-508
Journal	Melanoma Research
Volume	24
Issue number	5
DOIs	https://doi.org/10.1097/CMR.0000000000000099
Publication status	Published - 2014

Access to Document

10.1097/CMR.0000000000000099

Cite this

@article{4459738bedf64a1aaaefd92fb1cd8a78,

title = "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma",

abstract = "{\textcopyright} 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.",

author = "S.E. Bowyer and A.D. Rao and M. Lyle and S. Sandhu and G. Long and G.A. Mcarthur and J.M. Raleigh and R.J. Hicks and Michael Millward",

year = "2014",

doi = "10.1097/CMR.0000000000000099",

language = "English",

volume = "24",

pages = "504--508",

journal = "Melanoma Research",

issn = "0960-8931",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

TY - JOUR

T1 - Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

AU - Bowyer, S.E.

AU - Rao, A.D.

AU - Lyle, M.

AU - Sandhu, S.

AU - Long, G.

AU - Mcarthur, G.A.

AU - Raleigh, J.M.

AU - Hicks, R.J.

AU - Millward, Michael

PY - 2014

Y1 - 2014

N2 - © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.

AB - © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.

U2 - 10.1097/CMR.0000000000000099

DO - 10.1097/CMR.0000000000000099

M3 - Article

SN - 0960-8931

VL - 24

SP - 504

EP - 508

JO - Melanoma Research

JF - Melanoma Research

IS - 5

ER -

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Abstract

Access to Document

Fingerprint

Cite this